While the equity markets have clear appetite for new biotech paper, the oversubscribed Athyrium Opportunities Fund L.P. shows investors are not turning a blind eye to alternative financing vehicles.

Athyrium Capital Management and partner Neuberger Berman closed the life sciences credit fund at $507 million last week. The size is well above the original target of $350 million.